ADC Therapeutics SA
NYSE:ADCT

  • LAST PRICE
    2.9400
  • TODAY'S CHANGE (%)
    0.0900 (3.1579%)
  • Bid / Lots
    2.8600/ 26
  • Ask / Lots
    3.0000/ 11
  • Open / Previous Close
    2.8900 / 2.8500
  • Day Range
    2.8000
    2.9900
  • 52 Week Range
    0.3599
    6.0400
  • Volume
    313,010

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ADCT
ADC Therapeutics SA
275.4M
-1.2x
---
PSTX
Poseida Therapeutics Inc
266.1M
-2.5x
---
ADAP
Adaptimmune Therapeutics PLC
271.1M
-3.4x
---
CDXS
Codexis Inc
210.7M
-2.7x
---
PSNL
Personalis Inc
322.6M
-3.9x
---
ENTA
Enanta Pharmaceuticals Inc
264.6M
-2.3x
---
As of 2024-08-21

Company Information

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Contact Information

Headquarters
Biopole, route de la Corniche 3BEPALINGES, Switzerland 1066
Phone
---
Fax
---

Executives

Non-Executive Chairman of the Board
Ron Squarer
Chief Executive Officer, Director
Ameet Mallik
Chief Financial Officer
Jose Carmona
Chief Scientific Officer
Patrick Van Berkel
Chief Legal Officer
Peter Graham

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$275.4M
Revenue (TTM)
$66.7M
Shares Outstanding
96.6M
ADC Therapeutics SA does not pay a dividend.
Beta
1.60
EPS
$-2.55
Book Value
$-1.80
P/E Ratio
-1.2x
Price/Sales (TTM)
4.1
Price/Cash Flow (TTM)
---
Operating Margin
-206.87%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.